|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The RHOA G17V mutation was found in 15 (75%) of 20 AITL and two (22%) of nine PTCL, NOS.
|
31394087 |
2019 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma.
|
28832024 |
2018 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Detection of the G17V RHOA mutations assists prompt and appropriate diagnosis of AITL.
|
29493850 |
2018 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent genetic analysis has identified frequent mutations in ten-eleven translocation 2 (TET2), DNA methyltransferase 3A (DNMT3A), isocitrate dehydrogenase 2 (IDH2) and ras homolog family member A (RHOA) in nodal T-cell lymphomas, including angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified.
|
28157189 |
2017 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recent genetic studies identified that the disease-specific G17V RHOA mutation, together with mutations in TET2, DNMT3A, and IDH2, is a hallmark of angioimmunoblastic T cell lymphomas (AITL).
|
28634614 |
2017 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas.
|
28945625 |
2017 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among these, CCR4 expression and the CD21(+) network in RHOA-mutated AITL cases were more extensive than in the RHOA mutation-negative AITL cases (P<0.05).
|
27158755 |
2016 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, mutations in TET2 and other epigenetic modifiers as well as RHOA have been identified in these diseases, particularly in angioimmunoblastic T-cell lymphoma (AITL).
|
26719098 |
2016 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The RHOA G17V mutation was identified in 63% of the AITL cases and in none of the PTCL-NOS cases.
|
26574844 |
2016 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genome wide sequencing studies have dissected the repertoire of the genetic alterations driving AITL uncovering a highly recurrent Gly17Val somatic mutation in the small GTPase RHOA and major role for mutations in epigenetic regulators, such as TET2, DNMT3A and IDH2, and signaling factors (e.g., FYN and CD28).
|
27177312 |
2016 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For example, genetic alterations have been discovered, including signal transducer and activator of transcription (STAT)3 and STAT5b mutations in several PTCLs, disease-specific ras homolog family member A (RHOA) mutations in angioimmunoblastic T cell lymphoma (AITL), and recurrent translocations at the dual specificity phosphatase 22 (DUSP22) locus in anaplastic lymphoma receptor tyrosine kinase (ALK)-negative anaplastic large cell lymphomas (ALCLs).
|
26431836 |
2015 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL, not otherwise specified (PTCL-NOS) samples.
|
24413734 |
2014 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using whole-exome and subsequent targeted sequencing, we recently identified G17V RHOA mutations in 60-70% of AITL and AITL-like PTCL-NOS cases but not in other hematologic cancers, including other T-cell malignancies.
|
25310466 |
2014 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
Biomarker
|
disease |
CTD_human |
Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.
|
24413737 |
2014 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mutation in Waldenström macroglobulinemia, the G17V RHOA mutation in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified, and the Y640F//D661Y/V/H/I//N647I STAT3 mutations in T-cell large granular lymphocytic leukemia.
|
24689848 |
2014 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our experimental data and modeling results suggest that the RHOA mutation encoding p.Gly17Val is a driver mutation in AITL.
|
24584070 |
2014 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
Biomarker
|
disease |
CTD_human |
A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma.
|
24584070 |
2014 |
|
Angioimmunoblastic Lymphadenopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that impaired RHOA function in cooperation with preceding loss of TET2 function contributes to AITL-specific pathogenesis.
|
24413737 |
2014 |
|
Malignant neoplasm of stomach
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer.
|
31771969 |
2020 |
|
Malignant neoplasm of stomach
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, NORAD's expression was positively correlated with RhoA and ROCK1 expressions in GC based on The Cancer Genome Atlas (TCGA) database.
|
31115002 |
2019 |
|
Malignant neoplasm of stomach
|
0.390 |
Biomarker
|
disease |
BEFREE |
Moreover, an abundance of studies show RHOA association with Lauren classification diffuse subtype, in addition to poorly differentiated GC.
|
31156701 |
2019 |
|
Malignant neoplasm of stomach
|
0.390 |
Biomarker
|
disease |
BEFREE |
Expressions of Ras Homolog Gene Family, Member A (RhoA) and Cyclooxygenase-2 (COX-2) Proteins in Early Gastric Cancer and Their Role in the Development of Gastric Cancer.
|
28624843 |
2017 |
|
Malignant neoplasm of stomach
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
CDH1 alterations, but not RHOA mutations, were associated with shorter survival times of patients, which might account for the aggressive clinical course of early-onset gastric cancer.
|
28522256 |
2017 |
|
Malignant neoplasm of stomach
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Here, we show: i) differences in RHOA expression patterns, and its pathway activity, between Asian and Caucasian GC tumors; ii) in vitro and in vivo perturbed RHOA expression inhibits GC cell growth in high RHOA-expressing cell lines; iii) inverse correlation between RHOA and RHOB expression; and iv) an innovative small molecule design strategy for RHOA inhibitors.
|
27806312 |
2016 |
|
Malignant neoplasm of stomach
|
0.390 |
Biomarker
|
disease |
BEFREE |
We performed a thorough review of 87 diffuse-type gastric cancers, including 22 RHOA-mutated and 65 RHOA wild-type gastric cancers.
|
25823974 |
2016 |